molecular
diagnost
revolutionis
clinic
practic
infecti
diseas
effect
signific
acutecar
set
time
accur
diagnost
tool
critic
patient
treatment
decis
outcom
pcr
welldevelop
molecular
techniqu
wide
rang
alreadi
fulfil
potenti
clinic
applic
includ
specif
broadspectrum
pathogen
detect
evalu
emerg
novel
infect
surveil
earli
detect
biothreat
agent
antimicrobi
resist
profil
pcrbase
method
may
also
cost
effect
rel
tradit
test
procedur
advanc
technolog
need
improv
autom
optimis
detect
sensit
specif
expand
capac
detect
multipl
target
simultan
multiplex
review
provid
uptod
look
gener
principl
diagnost
valu
limit
current
pcrbase
platform
evolv
bench
bedsid
pathogen
identif
scope
problem
usa
hospit
report
well
million
case
recognis
infectiousdiseaserel
ill
annual
significantli
greater
number
remain
unrecognis
inpati
commun
set
result
substanti
morbid
mortal
critic
time
intervent
infecti
diseas
reli
rapid
accur
detect
pathogen
acutecar
set
beyond
recent
anthraxrel
bioterrorist
event
outbreak
sever
acut
respiratori
syndrom
sar
underscor
import
rapid
diagnost
earli
inform
decisionmak
relat
patient
triag
infect
control
treatment
vaccin
lifeanddeath
consequ
patient
health
provid
public
unfortun
despit
recognit
outcom
infecti
ill
directli
associ
time
pathogen
identif
convent
hospit
laboratori
remain
encumb
tradit
slow
multistep
culturebas
assay
preclud
applic
diagnost
test
result
acut
criticalcar
set
limit
convent
laboratori
includ
extrem
prolong
assay
time
fastidi
pathogen
sever
week
requir
addit
test
wait
time
characteris
detect
pathogen
ie
discern
speci
strain
virul
factor
antimicrobi
resist
diminish
test
sensit
patient
receiv
antibiot
inabl
cultur
certain
pathogen
diseas
state
associ
microbi
infect
failur
either
clinic
judgment
diagnost
technolog
provid
quick
accur
data
identifi
pathogen
infect
patient
lead
clinician
adopt
conserv
manag
approach
empir
intraven
antibiot
therapi
common
pcrbase
diagnost
infecti
diseas
use
limit
futur
applic
acutecar
set
acutecar
set
emerg
depart
intens
care
unit
offer
advantag
maximum
patient
safeti
improv
outcom
benefit
conserv
manag
may
offset
howev
ad
cost
potenti
iatrogen
complic
associ
unnecessari
treatment
hospitalis
well
increas
rate
antimicrobi
resist
rapid
reliabl
diagnost
assay
allow
accur
identif
infect
patient
inform
earli
therapeut
intervent
would
thu
invalu
emerg
critic
care
physician
decad
molecular
test
herald
diagnost
tool
new
millennium
whose
ultim
potenti
could
render
tradit
hospit
laboratori
obsolet
howev
evolut
novel
diagnost
tool
difficult
question
arisen
regard
role
test
assess
clinic
infecti
diseas
molecular
diagnost
continu
flow
bench
bedsid
clinician
must
acquir
work
knowledg
principl
diagnost
valu
limit
vari
assay
discuss
promis
molecular
diagnost
techniqu
infecti
diseas
hospitalbas
set
emphasi
pcrbase
method
sinc
reach
greatest
matur
exist
assay
current
futur
applic
describ
framework
describ
limit
encount
well
specul
regard
potenti
effect
develop
patient
physician
hospit
societ
perspect
provid
first
nucleicacidbas
assay
use
dna
probe
technolog
dna
probe
short
label
singlestrand
segment
dna
design
synthesis
hybridis
target
complementari
sequenc
microbi
dna
contrast
tradit
culturebas
method
microbi
identif
reli
phenotyp
characterist
molecular
fingerprint
techniqu
reli
sequencebas
hybridis
chemistri
confer
greater
specif
pathogen
identif
direct
detect
target
microbi
dna
clinic
sampl
also
elimin
need
cultiv
drastic
reduc
time
requir
report
result
descript
dna
hybridis
probe
detect
enterotoxigen
escherichia
coli
stool
sampl
rais
hope
nucleicacidbas
technolog
would
eventu
replac
tradit
cultur
techniqu
sinc
time
howev
restrain
approach
adopt
due
recognit
technic
limit
methodolog
notabl
larg
amount
start
target
dna
requir
analysi
result
poor
detect
sensit
attain
optimum
sensit
critic
clinic
applic
research
sought
directli
amplifi
target
microbi
dna
develop
pcr
techniqu
answer
need
provid
bestdevelop
wide
use
method
target
dna
amplif
approach
includ
amplif
hybridis
probe
eg
ligas
chain
reaction
qbeta
replicas
amplif
amplif
signal
gener
hybridis
probe
eg
branch
dna
hybrid
captur
transcriptionbas
amplif
eg
nucleicacidsequencebas
amplif
transcriptionmedi
amplif
also
incorpor
variou
detect
system
detail
descript
technolog
beyond
scope
review
well
summaris
elsewher
pcr
enzymedriven
process
amplifi
short
region
dna
vitro
method
reli
know
least
partial
sequenc
target
dna
priori
use
design
oligonucleotid
primer
hybridis
specif
target
sequenc
pcr
target
dna
copi
thermost
dna
polymeras
enzym
presenc
nucleotid
primer
multipl
cycl
heat
cool
thermocycl
produc
round
target
dna
denatur
primer
hybridis
primer
extens
target
dna
amplifi
exponenti
figur
theoret
method
potenti
gener
billion
copi
target
dna
singl
copi
less
h
detail
discuss
basic
principl
pcr
see
refer
past
two
decad
pcr
extens
modifi
expand
util
versatil
multiplex
pcr
enabl
simultan
detect
sever
target
sequenc
incorpor
multipl
set
primer
increas
sensit
specif
doubl
amplif
step
done
appropri
design
nest
primer
amplif
may
made
less
specif
detect
diverg
genom
randomis
portion
primer
set
final
rna
rather
dna
detect
convert
rna
complementari
dna
copi
amplifi
socal
revers
transcriptas
pcr
rtpcr
enabl
evalu
rna
virus
viabl
organ
signific
advanc
pcr
technolog
quantit
realtim
pcr
amplif
detect
amplifi
product
coupl
singl
reaction
vessel
purpos
clinic
applic
process
repres
major
breakthrough
sinc
elimin
need
labori
postamplif
process
ie
gel
electrophoresi
convent
need
amplicon
detect
allow
measur
product
simultan
dna
synthesi
one
approach
realtim
monitor
amplicon
product
use
fluoresc
dna
intercal
dye
sybrgreen
bind
nonspecif
doublestrand
dna
gener
amplif
popular
altern
approach
use
fluorescentlabel
intern
dna
probe
specif
anneal
within
target
amplif
region
choic
probe
format
depend
compat
hybridis
chemistri
experiment
design
variat
probe
format
includ
taqman
appli
biosystem
figur
fluoresc
reson
energi
transfer
fret
molecular
beacon
probe
regardless
format
chosen
intern
probe
emit
fluoresc
signal
amplif
cycl
presenc
target
sequenc
signal
intens
increas
proport
amount
amplifi
product
gener
amount
start
templat
specimen
quantifi
compar
exact
cycl
number
amplifi
product
accumul
significantli
baselin
prederiv
quantit
standard
develop
autom
instrument
quantit
capac
insur
reproduc
practic
advantag
realtim
pcr
convent
pcr
thu
myriad
includ
speed
simplic
reproduc
quantit
capac
pcrbase
diagnost
effect
develop
wide
rang
microb
due
incred
sensit
specif
speed
amplif
pcr
champion
infecti
diseas
expert
identifi
organ
grown
vitro
instanc
exist
cultur
techniqu
insensit
andor
need
prolong
incub
time
applic
clinic
arena
howev
met
variabl
success
far
limit
number
assay
approv
us
food
drug
administr
fda
tabl
fewer
still
achiev
univers
accept
clinic
practic
furthermor
surprisingli
limit
effort
focus
har
timesav
diagnost
emerg
depart
acut
criticalcar
set
time
essenc
discuss
progress
made
obstacl
remain
address
follow
increas
number
genom
infecti
pathogen
sequenc
catalogu
gene
exploit
serv
amplif
target
fundament
design
clinic
use
diagnost
test
result
past
decad
number
pcr
assay
develop
commerci
hospitalbas
laboratori
inhous
continu
expand
among
assay
develop
detect
specif
microb
three
describ
detail
along
discuss
pro
con
rel
convent
diagnost
methodolog
tabl
one
earliest
recognis
applic
pcr
clinic
practic
detect
mycobacterium
tuberculosi
diseas
characterist
favour
develop
nonculturebas
test
tuberculosi
includ
weeklong
monthlong
delay
associ
standard
test
publichealth
imper
associ
earli
recognit
isol
treatment
infect
patient
two
pcrbase
assay
approv
fda
direct
detect
tuberculosi
clinic
specimen
tabl
although
assay
result
signific
improv
time
diagnosi
fda
approv
use
time
diagnost
adjunct
convent
smear
cultur
nonetheless
recent
studi
suggest
widespread
use
assay
may
significantli
affect
patient
manag
clinic
outcom
cost
efficaci
potenti
yet
unrealis
applic
assay
use
acutecar
set
includ
earlier
inform
decisionmak
appropri
use
isol
bed
high
preval
site
region
outbreak
isol
bed
scarc
use
pcrbase
diagnost
set
howev
balanc
cost
expertis
time
associ
routin
aroundtheclock
avail
test
discuss
detail
anoth
pcrbase
diagnost
assay
gain
widespread
accept
chlamydia
trachomati
convent
detect
system
organ
ie
cultur
direct
antigen
test
immunoassay
limit
requir
specialis
facil
cultur
fastidi
microb
well
inadequ
sensit
specif
immunoassay
rel
gold
standard
cultur
result
laboratori
develop
subsequ
clinic
valid
test
indic
excel
sensit
specif
pcr
assay
lead
commerci
develop
tabl
proven
efficaci
pcr
assay
genit
urin
sampl
result
applic
rang
clinic
set
extens
phase
pcr
probe
cleav
exonucleas
activ
taq
polymeras
therebi
releas
report
quencher
produc
increas
report
emiss
intens
detect
quantifi
amplif
continu
amount
report
dye
signal
measur
proport
amount
pcr
product
made
recent
routin
screen
emerg
depart
patient
consid
risk
sexual
transmit
diseas
although
studi
acutecar
set
yet
use
pcr
assay
c
trachomati
site
real
time
thu
take
full
advantag
speed
pcr
routin
use
assay
aforement
studi
result
nearli
threefold
greater
rate
diseas
detect
treatment
rel
standard
care
distinguish
lifethreaten
caus
fever
benign
caus
children
fundament
clinic
dilemma
face
clinician
especi
infect
central
nervou
system
consid
bacteri
caus
mening
highli
aggress
gener
differenti
clinic
basi
asept
mening
benign
condit
gener
appropri
outpati
manag
cultur
method
often
take
sever
day
show
posit
result
confound
poor
sensit
falseneg
find
patient
receiv
empir
antimicrobi
one
well
develop
assay
potenti
influenc
manag
patient
acutecar
set
allow
earli
rapid
diagnosi
diseas
viral
caus
test
applic
pcr
assay
enterovir
mening
seen
highli
sensit
report
result
within
day
preliminari
clinic
trial
shown
signific
decreas
hospit
cost
due
decreas
durat
hospit
stay
cours
antibiot
therapi
viral
pcr
assay
routin
avail
includ
herp
simplex
viru
cytomegaloviru
epsteinbarr
viru
hepat
virus
hiv
proven
costsav
role
clinic
practic
includ
detect
otherwis
difficult
diagnos
infect
newli
realis
capac
monitor
progress
diseas
respons
therapi
vital
manag
chronic
infecti
diseas
increas
number
genom
infecti
pathogen
sequenc
catalogu
gene
exploit
serv
amplif
target
result
number
pcr
assay
develop
commerci
inhous
continu
expand
notion
univers
detect
system
propos
identif
class
pathogen
speak
directli
futur
potenti
effect
pcrbase
assay
clinic
practic
emerg
acut
criticalcar
set
experiment
work
focus
use
sequenc
rrna
gene
evolutionarili
conserv
gene
seen
exclus
bacteri
speci
design
primer
complementari
region
investig
theori
establish
presenc
bacteria
otherwis
steril
clinic
specimen
cerebrospin
fluid
whole
blood
clinic
applic
profound
acutecar
physician
could
rapidli
identifi
presenc
bacteraemia
previou
empir
decisionmak
could
abandon
review
pcrbase
diagnost
favour
educ
practic
allow
appropri
expediti
decisionmak
need
antibiot
therapi
hospitalis
principl
approach
could
appli
taxonom
group
pathogen
eg
genu
speci
famili
virus
fungi
exploit
common
featur
class
organ
broadrang
pcr
assay
design
valid
techniqu
eubacteri
detect
focus
high
yield
clinic
set
expediti
identif
presenc
system
bacteri
infect
immedi
high
morbid
mortal
consequ
notabl
clinic
trial
includ
assess
patient
risk
infect
endocard
febril
infant
risk
sepsi
febril
neutropen
cancer
patient
critic
ill
patient
intens
care
unit
sever
studi
report
promis
result
sensit
specif
bacteraemia
well
signific
technic
difficulti
remain
prevent
gener
accept
assay
clinic
hospit
see
limit
one
signific
investig
role
broadrang
pcr
use
molecular
petri
dish
identifi
emerg
exist
infecti
caus
diseas
previous
describ
idiopath
dna
amplifi
use
broadrang
approach
may
contain
interven
sequenc
inform
phylogenet
specif
uniqu
microb
compar
exist
microbi
genet
databas
exampl
sequenc
rrna
gene
amplifi
via
highli
conserv
primer
set
led
identif
bartonella
hensela
bacillari
angiomatosi
tropheryma
whipplei
uncultur
bacillu
associ
whippl
diseas
recent
epidemiolog
studi
suggest
strong
associ
chlamydia
pneumonia
coronari
arteri
diseas
serv
exampl
possibl
widespread
yet
undiscov
link
pathogen
host
may
ultim
lead
new
insight
pathogenesi
develop
novel
life
sustain
save
therapeut
recent
highprofil
investig
use
broadrang
pcr
molecular
identif
coronaviru
caus
agent
sar
variant
approach
pcr
assay
develop
broadbas
primer
degener
sequenc
design
detect
unknown
virus
use
randomli
amplifi
genet
content
infect
clinic
isol
subset
amplifi
sequenc
show
homolog
genu
coronaviru
consist
confirmatori
laboratori
test
result
soon
afterward
coronavirusspecif
pcr
assay
develop
rapid
laboratori
diagnosi
sar
notabl
advanc
came
week
first
report
diseas
surfaceda
verit
tour
de
forc
bespeak
power
broadrang
pcr
multidrugresist
pathogen
rise
earli
antimicrobi
resist
profil
crucial
time
object
treatment
infect
patient
well
broader
publichealth
surveil
convent
test
type
limit
prolong
cultur
time
h
poor
accuraci
due
variabl
inoculum
size
cultur
condit
address
shortcom
nucleicacidbas
assay
advanc
genet
mechan
review
pcrbase
diagnost
although
presenc
resist
gene
necessarili
impli
express
confer
phenotyp
resist
absenc
establish
lack
resist
particular
genet
mechan
exampl
meticillin
resist
mediat
meca
gene
distinct
featur
meticillin
resist
heterogen
express
typic
phenotyp
suscept
test
use
assess
resist
meticillinresist
strain
may
seem
fals
suscept
antibiot
vitro
reason
direct
detect
meca
gene
pcr
desir
high
detect
sensit
specif
meca
pcr
gain
wide
accept
becom
reliabl
method
identifi
meticillinresist
staphylococcu
aureu
mrsa
pcrbase
resist
test
tuberculosi
also
develop
detect
rifampicin
resist
rifampicin
resist
well
characteris
confer
mutat
within
short
sequenc
rpob
gene
tuberculosi
result
aminoacid
substitut
rpob
subunit
rna
polymeras
line
probe
assay
lipa
innogenet
commerci
avail
pcrbase
assay
target
mutationpron
segment
rpob
gene
correl
standard
resistancedetect
method
shown
provid
clinician
drastic
reduct
detect
time
critic
treatment
decis
genotyp
analysi
tuberculosi
drug
resist
challeng
due
number
mutat
genet
loci
involv
technic
innov
ie
multiplex
pcr
dna
microarray
allow
simultan
amplif
analysi
multipl
target
sequenc
like
provid
mean
surmount
later
limit
everincreas
evid
support
prognost
valu
identifi
drugresist
mutat
routin
genotyp
resist
test
standard
care
treatment
hivinfect
patient
pcr
follow
nucleotid
sequenc
commonli
use
method
although
genotyp
test
complex
typic
antimicrobi
suscept
test
abil
detect
mutat
concentr
low
affect
drug
suscept
phenotyp
assay
provid
insight
potenti
resist
emerg
also
advantag
detect
transit
mutat
caus
drug
resist
indic
presenc
select
drug
pressur
potenti
import
individu
patient
treatment
decis
increas
threat
bioterror
gain
consider
attent
light
anthrax
outbreak
came
septemb
terrorist
attack
becom
increasingli
appar
respons
rapid
recognit
accur
diagnosi
real
suspect
bioterror
event
fall
princip
frontlin
acutecar
physician
critic
initi
appropri
respons
measur
unfortun
seen
anthrax
episod
clinic
present
bioterror
victim
may
nonspecif
difficult
distinguish
commonli
encount
diseas
process
previous
describ
limit
convent
culturebas
assay
make
test
wholli
inadequ
detect
bioterror
agent
suspect
clinic
outbreak
furthermor
tradit
microbiolog
method
requir
prolong
incub
increas
biohazard
risk
hospit
laboratori
due
unnecessari
propag
bioterror
pathogen
culturebas
system
wide
recognit
limit
led
recent
develop
refin
pcrbase
assay
number
categori
bioterror
agent
includ
variola
major
bacillu
anthraci
yersinia
pesti
francisella
tularensi
pcr
diagnost
bioterror
agent
like
use
diagnosi
symptomat
individu
well
larger
scale
screen
expos
victim
preclin
phase
would
candid
earli
prophylact
therapi
although
bioterrorisminduc
ill
resembl
natur
outbreak
possibl
caus
bioterror
agent
genet
engin
increas
virul
acquir
resist
antibiot
vaccin
produc
phenotyp
characterist
resembl
multipl
simultan
infect
socal
binari
agent
via
insert
recombin
gene
case
like
nucleicacidbas
approach
invalu
convent
detect
method
sinc
easili
adapt
capabl
uncov
detail
inform
embed
genet
sequenc
pcr
expens
convent
approach
direct
cost
pcr
reagent
equip
dedic
space
personnel
train
labour
report
high
us
per
reaction
even
among
pcr
method
variabl
cost
expens
fluorogenicbas
system
moreov
labour
intens
need
assay
well
technic
limit
thermocycl
multipl
run
pcr
simultan
prevent
routin
aroundtheclock
test
clinic
set
hand
continu
refin
pcr
technolog
well
improv
autom
reproduc
via
high
throughput
robot
probabl
lead
increas
demand
mark
cost
reduct
rate
competit
tradit
method
alreadi
develop
report
neisseria
gonorrhoea
c
trachomati
pcr
test
cost
around
per
reaction
assess
overal
benefit
pcr
howev
direct
monetari
cost
consider
sinc
assay
sever
signific
advantag
tradit
method
one
studi
took
global
methodolog
approach
cost
involv
assess
perinat
screen
group
b
streptococcu
use
pcr
versu
cultur
techniqu
consid
variabl
assay
addit
direct
monetari
cost
includ
infect
avert
mortal
infant
disabl
hospit
stay
societ
benefit
healthi
infant
overal
author
conclud
benefit
pcr
outweigh
cost
notabl
result
reach
even
without
inclus
import
review
difficulttomeasur
paramet
societ
benefit
decreas
drug
resist
due
target
therapi
made
possibl
pcr
assay
princip
shortcom
appli
pcr
assay
clinic
set
includ
falseposit
result
background
dna
contamin
potenti
falseneg
test
result
detect
sensit
exceed
clinic
signific
limit
detect
space
assay
platform
simultan
identif
multipl
speci
virul
factor
drug
resist
widespread
use
pcr
clinic
set
hamper
larg
background
contamin
exogen
sourc
dna
pathogenspecif
assay
predomin
sourc
contamin
deriv
carryov
product
earlier
pcr
reaction
harbour
transmit
pcr
reagent
tube
pipett
laboratori
surfac
coupl
robust
amplif
power
pcr
even
minor
amount
carryov
contamin
may
serv
substrat
amplif
lead
falseposit
result
meticul
control
measur
good
laboratori
practic
physic
separ
preamplif
postamplif
area
reduc
contamin
risk
foolproof
use
enzymat
inactiv
carryov
dna
ie
uracil
nglycosylas
reduc
contamin
risk
contamin
issu
pronounc
assay
use
univers
primer
target
conserv
region
eubacteri
rrna
gene
ubiquit
presenc
eubacteri
dna
either
environ
work
reagent
may
lead
falseposit
find
attempt
decontamin
pcr
materi
involv
nearli
known
method
destroy
dna
includ
ultraviolet
irradi
chemic
treatment
enzymat
digest
none
method
shown
entir
effect
without
signific
diminut
assay
sensit
recent
report
altern
method
use
sizebas
ultrafiltr
step
reduc
contamin
dna
pcr
reagent
primer
dna
polymeras
amplif
although
method
decontamin
shown
effect
without
compromis
detect
sensit
vitro
valid
optimis
method
clinic
sampl
need
studi
importantli
effect
reliabl
method
decontamin
yet
develop
step
outsid
assay
proper
sampl
collect
prepar
toward
end
one
promis
area
investig
involv
develop
method
integr
sampl
prepar
amplif
detect
singl
platform
socal
labonachip
selfcontain
microchip
platform
thu
hold
promis
best
mean
decontamin
overal
assay
effici
pcr
assay
microbi
detect
may
give
falseneg
result
two
princip
reason
rel
small
sampl
volum
permiss
pcr
reaction
problem
associ
pcr
process
sampl
volum
pcr
assay
accommod
quit
small
rel
volum
use
convent
cultur
method
case
concentr
infecti
organ
low
assay
may
yield
falseneg
find
account
dna
extract
purif
step
usual
perform
pcr
amplif
mean
concentr
total
dna
larger
sampl
volum
addit
method
optimis
start
concentr
target
dna
pcr
reaction
includ
select
specimen
sourc
eg
cerebrospin
fluid
specimen
fraction
eg
buffi
coat
instead
whole
blood
highest
abund
microbi
dna
dna
extract
briefli
cultiv
sampl
increas
microbi
load
dna
extract
introduc
specif
captur
probe
concentr
microbi
dna
given
sampl
sever
sampl
process
obstacl
may
also
lead
falseneg
find
three
commonli
encount
problem
inadequ
remov
pcr
inhibitor
sampl
haemoglobin
blood
cultur
media
urin
sputum
ineffect
releas
microbi
dna
content
cell
poor
dna
recoveri
extract
purif
step
method
ensur
best
sampl
process
includ
incorpor
intern
amplif
control
eg
human
gene
pcr
assay
monitor
presenc
purifi
sampl
dna
well
potenti
pcr
inhibitor
induc
variou
chaotrop
enzymat
thermal
method
cell
lysi
effect
liber
microbi
dna
content
vari
effect
measur
effort
improv
assay
detect
sensit
may
need
individu
adjust
base
assay
clinic
applic
microbi
pathogen
interest
pcr
assay
may
detect
microbi
pathogen
concentr
previous
establish
gold
standard
refer
method
distinguish
whether
result
repres
falseposit
find
establish
clinic
signific
find
challeng
past
discrep
analysi
base
result
addit
ancillari
test
use
provid
estim
sensit
specif
presenc
imperfect
gold
standard
one
exampl
seen
assess
novel
nucleic
acidbas
assay
detect
c
trachomati
studi
fals
posit
dnaamplif
posit
tissu
cultur
neg
adjud
either
antigen
detect
method
anoth
wellestablish
dnaamplif
test
despit
popular
recent
concern
rais
regard
potenti
bia
incur
discrep
analysi
favour
new
test
issu
complet
resolv
complex
clinic
interpret
posit
pcr
find
underscor
one
studi
report
univers
pcr
assay
use
primer
conserv
region
rrna
gene
amplifi
eubacteri
dna
blood
sampl
healthi
peopl
unknown
whether
find
indic
latent
diseas
process
subclin
colonis
moreov
find
microbi
dna
detect
even
success
antimicrobi
treatment
suggest
assay
detect
viabl
nonviabl
organ
clearli
interpret
guidelin
base
correl
test
result
clinic
present
exist
standard
requir
assay
use
definit
diagnosi
andor
treatment
decis
one
breakthrough
establish
mean
posit
pcr
result
involv
develop
reliabl
quantit
measur
pathogen
load
tradit
pcr
assay
use
primarili
dichotom
outcom
innov
realtim
pcr
method
allow
quantit
measur
start
templat
sampl
probabl
use
differenti
benign
colonis
either
latent
activ
diseas
nonpcr
amplif
method
quantit
capac
includ
branch
dna
nucleicacidsequencebas
amplif
quantif
pathogen
load
alreadi
well
establish
clinic
virolog
eg
cytomegaloviru
hepat
b
viru
hepat
c
viru
epsteinbarr
viru
proven
use
assess
diseas
sever
monitor
treatment
efficaci
valu
import
pcrbase
pathogen
quantif
clinic
bacteriolog
remain
investig
altern
innov
regard
pcr
technolog
may
help
differenti
viabl
nonviabl
organ
import
clinic
practic
decis
rna
known
rapidli
degrad
typic
halflif
minut
cell
death
thu
propos
accur
indic
viabl
microorgan
clinic
situat
detect
rna
speci
rtpcr
shown
correl
well
presenc
viabl
organ
effect
use
monitor
antibiot
therapi
clinic
applic
rnabas
approach
need
improv
howev
hamper
develop
difficulti
extract
detect
concentr
intact
rna
small
number
bacteria
convent
method
pathogen
detect
supplant
pcrbase
assay
latter
elabor
characteris
detect
pathogen
describ
previous
genet
sequenc
contain
rich
sourc
inform
analys
ascertain
pathogen
speci
strain
virul
factor
antimicrobi
suscept
howev
singl
reaction
simultan
amplif
sever
target
gene
need
repeat
amplif
differ
primer
pair
socal
multiplex
notori
difficult
sinc
often
one
target
sequenc
amplifi
recent
studi
shown
pcr
use
simultan
reproduc
amplif
multipl
dna
fragment
singl
reaction
provid
singl
primer
set
use
amplif
fragment
repetitivesequencebas
pcr
reppcr
use
consensu
pcr
primer
amplifi
dna
sequenc
locat
success
repetit
element
eubacteri
genom
shown
simultan
amplifi
fragment
differ
size
allow
discrimin
bacteria
subspeci
level
conceptu
breakthrough
led
variou
investig
develop
explor
variou
technic
approach
har
idea
exploit
conserv
variabl
sequenc
rrna
gene
shown
use
quantit
pcr
singl
consensu
primer
set
multiplex
amplifi
multipl
speci
rrna
gene
equal
effici
similarli
ligationdepend
pcr
figur
padlock
probe
roll
circl
amplif
figur
probe
amplif
method
also
shown
multipl
genet
target
queri
simultan
use
singl
primer
pair
amplif
assay
reli
multipl
oligonucleotid
probe
contain
uniqu
target
sequenc
consensu
primer
sequenc
amplifi
presenc
target
progress
approach
could
greatli
enhanc
throughput
genotyp
pathogen
detect
may
repres
next
gener
pcrbase
assay
hold
tremend
promis
regard
clinic
applic
even
problem
resolv
best
way
analys
result
pcr
product
remain
unclear
pcr
product
detect
analysi
typic
achiev
use
gelelectrophoresi
sequenc
techniqu
approach
labori
timeconsum
detract
clinic
applic
introduct
realtim
pcr
technolog
potenti
use
differenti
label
fluoresc
probe
simultan
identif
multipl
amplifi
product
singl
assay
hold
promis
unfortun
current
abil
spectral
differenti
multipl
fluoresc
signal
quit
limit
anoth
possibl
approach
use
analys
multipl
amplifi
sequenc
incorpor
microarray
technolog
dna
microarray
construct
spatial
isol
specif
genom
sequenc
prearrang
area
microchip
fluoresc
label
amplif
product
allow
anneal
complementari
sequenc
chip
result
pattern
spectral
analys
main
advantag
use
microarray
pathogen
detect
potenti
larg
number
target
sequenc
system
discrimin
simultan
use
microarray
technolog
pathogen
detect
still
develop
phase
howev
effort
improv
sensit
reproduc
streamlin
approach
complex
data
analysi
still
need
platform
use
clinic
final
novel
approach
analys
amplifi
product
mass
spectrometri
recent
advent
matrix
assist
laser
descriptionionis
maldi
technolog
coupl
time
flight
mass
spectrometri
tofm
creat
robust
mean
characteris
mostli
protein
increasingli
nucleic
acid
malditofm
organ
moleculefor
exampl
amplifi
producti
ionis
subsequ
identifi
base
masstocharg
ratio
figur
advantag
malditofm
lie
inher
accuraci
highspe
second
signal
acquisit
make
technolog
attract
candid
highthroughput
dna
analysi
realtim
pcrbase
platform
hold
great
promis
replac
convent
laboratorybas
test
futur
pointofcar
test
advanc
autom
integr
specimen
prepar
target
identif
miniaturis
becom
much
easier
bring
analys
near
bedsid
done
lesstrain
personnel
abil
interfac
high
throughput
pcr
system
alreadi
seen
mani
new
autom
extract
instrument
technic
limit
pcr
instrument
run
overlap
reaction
parallel
restrict
analys
batch
therebi
compromis
assay
overal
turnaround
time
howev
new
gener
thermocycl
eg
smartcycl
cepheid
separ
pcr
reaction
uniqu
set
cycl
protocol
data
analysi
done
simultan
furthermor
recent
introduct
handheld
batteryoper
realtim
pcr
instrument
bioseeq
smith
detectionedgewood
bioseeq
latest
iter
move
trend
laboratori
near
patient
test
ultim
labonachip
technolog
matur
routin
pointofcar
test
realis
true
effect
pcr
develop
true
pointofcar
test
remain
seen
signific
practic
regulatori
requir
slow
often
halt
transit
laboratori
develop
bedsid
applic
complianc
feder
state
local
regul
must
met
oper
pointofcar
test
devic
novel
test
must
go
complex
timeconsum
process
fda
approv
inhous
assay
strict
clinic
laboratori
improv
amend
requir
must
met
defin
oper
characterist
assay
rel
current
gold
standard
institut
resourc
manpow
issu
cost
effect
also
care
consid
make
decis
practic
replac
tradit
diagnost
methodolog
addit
programmat
step
true
pointofcar
test
must
develop
insur
effect
includ
oper
turnaround
time
vs
speed
test
educ
practition
interpret
result
develop
protocol
optim
treatment
decisionmak
base
result
novel
test
establish
qualiti
assur
qualiti
improv
programm
pcrbase
technolog
continu
matur
issu
need
systemat
address
order
realis
benefit
routin
patient
care
pcr
technolog
offer
great
potenti
arena
infecti
diseas
univers
reliabl
infecti
diseas
diagnost
system
certainli
becom
fundament
tool
evolv
diagnost
armamentarium
centuri
clinician
frontlin
acut
care
physician
physician
work
disast
set
quick
univers
pcr
assay
panel
pcr
assay
target
categori
pathogen
involv
specif
syndrom
mening
pneumonia
sepsi
would
allow
rapid
triag
earli
aggress
target
therapi
resourc
could
thu
appropri
appli
patient
suspect
infect
rapidli
riskstratifi
differ
treatment
set
depend
pathogen
virul
abil
discern
speci
subtyp
would
allow
precis
decisionmak
regard
antimicrobi
agent
patient
colonis
highli
contagi
pathogen
could
appropri
isol
entri
medic
set
without
delay
target
therapi
would
diminish
develop
antibiot
resist
identif
antibioticresist
strain
would
permit
precis
pharmacolog
intervent
physician
patient
would
benefit
less
repetit
test
elimin
wait
time
tradit
laboratori
result
furthermor
link
data
manag
system
local
region
nation
would
allow
effect
epidemiolog
surveil
obviou
benefit
antibiot
select
control
diseas
outbreak
certain
individu
patient
benefit
directli
approach
patient
unrecognis
difficulttodiagnos
infect
could
identifi
treat
promptli
inpati
stay
would
reduc
concomit
decreas
iatrogen
event
societ
benefit
need
care
explor
attent
rel
cost
novel
diagnost
relat
exist
standard
rer
serv
expert
consult
ibi
therapeut
divis
isi
pharmaceut
carlsbad
ca
usa
develop
diagnost
assay
use
pcr
mass
spectrometri
techniqu
data
review
identifi
search
medlin
refer
relev
articl
search
term
use
pcr
molecular
diagnost
emerg
infecti
diseas
bioterror
agent
antimicrobi
resist
dna
microarray
mass
spectrometri
english
languag
paper
consid
